• Je něco špatně v tomto záznamu ?

TSC2 pathogenic variants are predictive of severe clinical manifestations in TSC infants: results of the EPISTOP study

B. Ogórek, L. Hamieh, HM. Hulshof, K. Lasseter, K. Klonowska, H. Kuijf, R. Moavero, C. Hertzberg, B. Weschke, K. Riney, M. Feucht, T. Scholl, P. Krsek, R. Nabbout, AC. Jansen, B. Benova, E. Aronica, L. Lagae, P. Curatolo, J. Borkowska, K....

. 2020 ; 22 (9) : 1489-1497. [pub] 20200528

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020180

PURPOSE: To perform comprehensive genotyping of TSC1 and TSC2 in a cohort of 94 infants with tuberous sclerosis complex (TSC) and correlate with clinical manifestations. METHODS: Infants were enrolled at age <4 months, and subject to intensive clinical monitoring including electroencephalography (EEG), brain magnetic resonance imaging (MRI), and neuropsychological assessment. Targeted massively parallel sequencing (MPS), genome sequencing, and multiplex ligation-dependent probe amplification (MLPA) were used for variant detection in TSC1/TSC2. RESULTS: Pathogenic variants in TSC1 or TSC2 were identified in 93 of 94 (99%) subjects, with 23 in TSC1 and 70 in TSC2. Nine (10%) subjects had mosaicism. Eight of 24 clinical features assessed at age 2 years were significantly less frequent in those with TSC1 versus TSC2 variants including cortical tubers, hypomelanotic macules, facial angiofibroma, renal cysts, drug-resistant epilepsy, developmental delay, subependymal giant cell astrocytoma, and median seizure-free survival. Additionally, quantitative brain MRI analysis showed a marked difference in tuber and subependymal nodule/giant cell astrocytoma volume for TSC1 versus TSC2. CONCLUSION: TSC2 pathogenic variants are associated with a more severe clinical phenotype than mosaic TSC2 or TSC1 variants in TSC infants. Early assessment of gene variant status and mosaicism might have benefit for clinical management in infants and young children with TSC.

Affiliated Partner of ERN EpiCARE Vienna Austria

Amsterdam UMC University of Amsterdam Department of Pathology Amsterdam Neuroscience Amsterdam The Netherlands

Child Neurology and Psychiatry Unit Systems Medicine Department Tor Vergata University Rome Italy

Child Neurology Unit Neuroscience and Neurorehabilitation Department Bambino Gesù Children's Hospital IRCCS Rome Italy

Department of Child Neurology Brain Center University Medical Center Utrecht Utrecht The Netherlands

Department of Child Neurology Charité University Medicine Berlin Berlin Germany

Department of Child Neurology Medical University of Warsaw Warsaw Poland

Department of Development and Regeneration Section Pediatric Neurology University Hospitals KU Leuven Leuven Belgium

Department of Medicine Brigham and Women's Hospital Boston MA USA

Department of Molecular Genetics Institute of Bioorganic Chemistry Polish Academy of Sciences Poznan Poland

Department of Neurology and Epileptology The Children's Memorial Health Institute Warsaw Poland

Department of Pediatric Neurology Reference Centre for Rare Epilepsies Necker Enfants Malades Hospital University Paris Descartes Imagine Institute Paris France

Department of Pediatrics and Adolescent Medicine Medical University of Vienna

Diagnose und Behandlungszentrum für Kinder Vivantes Klinikum Neukölln Berlin Germany

GenomeScan Leiden The Netherlands

Image Sciences Institute University Medical Center Utrecht Utrecht The Netherlands

International Institute of Molecular and Cell Biology Warsaw Poland

Motol University Hospital Charles University Prague Czech Republic

Neurosciences Unit Queensland Children's Hospital South Brisbane Queensland Australia School of Medicine University of Queensland St Lucia Queensland Australia

Pediatric Neurology Unit UZ Brussel Neurogenetics Research Group Vrije Universiteit Brussel Brussels Belgium

Stichting Epilepsie Instellingen Nederland Heemstede the Netherlands Utrecht The Netherlands

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020180
003      
CZ-PrNML
005      
20210830101811.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41436-020-0823-4 $2 doi
035    __
$a (PubMed)32461669
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ogórek, Barbara $u Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
245    10
$a TSC2 pathogenic variants are predictive of severe clinical manifestations in TSC infants: results of the EPISTOP study / $c B. Ogórek, L. Hamieh, HM. Hulshof, K. Lasseter, K. Klonowska, H. Kuijf, R. Moavero, C. Hertzberg, B. Weschke, K. Riney, M. Feucht, T. Scholl, P. Krsek, R. Nabbout, AC. Jansen, B. Benova, E. Aronica, L. Lagae, P. Curatolo, J. Borkowska, K. Sadowski, D. Domańska-Pakieła, S. Janson, P. Kozlowski, M. Urbanska, J. Jaworski, S. Jozwiak, FE. Jansen, K. Kotulska, EPISTOP Consortium members, DJ. Kwiatkowski
520    9_
$a PURPOSE: To perform comprehensive genotyping of TSC1 and TSC2 in a cohort of 94 infants with tuberous sclerosis complex (TSC) and correlate with clinical manifestations. METHODS: Infants were enrolled at age <4 months, and subject to intensive clinical monitoring including electroencephalography (EEG), brain magnetic resonance imaging (MRI), and neuropsychological assessment. Targeted massively parallel sequencing (MPS), genome sequencing, and multiplex ligation-dependent probe amplification (MLPA) were used for variant detection in TSC1/TSC2. RESULTS: Pathogenic variants in TSC1 or TSC2 were identified in 93 of 94 (99%) subjects, with 23 in TSC1 and 70 in TSC2. Nine (10%) subjects had mosaicism. Eight of 24 clinical features assessed at age 2 years were significantly less frequent in those with TSC1 versus TSC2 variants including cortical tubers, hypomelanotic macules, facial angiofibroma, renal cysts, drug-resistant epilepsy, developmental delay, subependymal giant cell astrocytoma, and median seizure-free survival. Additionally, quantitative brain MRI analysis showed a marked difference in tuber and subependymal nodule/giant cell astrocytoma volume for TSC1 versus TSC2. CONCLUSION: TSC2 pathogenic variants are associated with a more severe clinical phenotype than mosaic TSC2 or TSC1 variants in TSC infants. Early assessment of gene variant status and mosaicism might have benefit for clinical management in infants and young children with TSC.
650    _2
$a předškolní dítě $7 D002675
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a mozaicismus $7 D009030
650    _2
$a mutace $7 D009154
650    _2
$a fenotyp $7 D010641
650    12
$a tuberózní skleróza $x diagnostické zobrazování $x genetika $7 D014402
650    _2
$a hamartin $x genetika $7 D000077004
650    _2
$a tuberin $x genetika $7 D000077005
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hamieh, Lana $u Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
700    1_
$a Hulshof, Hanna M $u Department of Child Neurology, Brain Center University Medical Center Utrecht, Utrecht, The Netherlands
700    1_
$a Lasseter, Kathryn $u Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
700    1_
$a Klonowska, Katarzyna $u Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
700    1_
$a Kuijf, Hugo $u Image Sciences Institute, University Medical Center Utrecht, Utrecht, The Netherlands
700    1_
$a Moavero, Romina $u Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University, Rome, Italy $u Child Neurology Unit, Neuroscience and Neurorehabilitation Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
700    1_
$a Hertzberg, Christoph $u Diagnose- und Behandlungszentrum für Kinder, Vivantes-Klinikum Neukölln, Berlin, Germany
700    1_
$a Weschke, Bernhard $u Department of Child Neurology, Charité University Medicine Berlin, Berlin, Germany
700    1_
$a Riney, Kate $u Neurosciences Unit, Queensland Children's Hospital, South Brisbane, Queensland, Australia/School of Medicine, University of Queensland, St Lucia, Queensland, Australia
700    1_
$a Feucht, Martha $u Department of Pediatrics and Adolescent Medicine, Medical University of Vienna; "Affiliated Partner of ERN EpiCARE", Vienna, Austria
700    1_
$a Scholl, Theresa $u Department of Pediatrics and Adolescent Medicine, Medical University of Vienna; "Affiliated Partner of ERN EpiCARE", Vienna, Austria
700    1_
$a Krsek, Pavel $u Motol University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Nabbout, Rima $u Department of Pediatric Neurology, Reference Centre for Rare Epilepsies, Necker-Enfants Malades Hospital, University Paris Descartes, Imagine Institute, Paris, France
700    1_
$a Jansen, Anna C $u Pediatric Neurology Unit, UZ Brussel, Neurogenetics Research Group, Vrije Universiteit Brussel, Brussels, Belgium
700    1_
$a Benova, Barbora $u Motol University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Aronica, Eleonora $u Amsterdam UMC, University of Amsterdam, Department of (Neuro)Pathology, Amsterdam Neuroscience, Amsterdam, The Netherlands $u Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede the Netherlands, Utrecht, The Netherlands
700    1_
$a Lagae, Lieven $u Department of Development and Regeneration Section Pediatric Neurology, University Hospitals KU Leuven, Leuven, Belgium
700    1_
$a Curatolo, Paolo $u Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University, Rome, Italy
700    1_
$a Borkowska, Julita $u Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland
700    1_
$a Sadowski, Krzysztof $u Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland
700    1_
$a Domańska-Pakieła, Dorota $u Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland
700    1_
$a Janson, Stef $u GenomeScan, Leiden, The Netherlands
700    1_
$a Kozlowski, Piotr $u Department of Molecular Genetics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland
700    1_
$a Urbanska, Malgorzata $u Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland
700    1_
$a Jaworski, Jacek $u International Institute of Molecular and Cell Biology, Warsaw, Poland
700    1_
$a Jozwiak, Sergiusz $u Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland $u Department of Child Neurology, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Jansen, Floor E $u Department of Child Neurology, Brain Center University Medical Center Utrecht, Utrecht, The Netherlands
700    1_
$a Kotulska, Katarzyna $u Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland
700    1_
$a Kwiatkowski, David J $u Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. dk@rics.bwh.harvard.edu
710    2_
$a EPISTOP Consortium members
773    0_
$w MED00186213 $t Genetics in medicine : official journal of the American College of Medical Genetics $x 1530-0366 $g Roč. 22, č. 9 (2020), s. 1489-1497
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32461669 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101811 $b ABA008
999    __
$a ok $b bmc $g 1690883 $s 1140626
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 22 $c 9 $d 1489-1497 $e 20200528 $i 1530-0366 $m Genetics in medicine $n Genet Med $x MED00186213
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace